Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Sanofi-Aventis S.A. (SNY)

Sanofi-Aventis S.A. (SNY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 110,212,880
  • Shares Outstanding, K 2,496,328
  • Annual Sales, $ 42,135 M
  • Annual Income, $ 5,101 M
  • 60-Month Beta 0.53
  • Price/Sales 2.69
  • Price/Cash Flow 8.41
  • Price/Book 1.58

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate 0.69
  • Number of Estimates 3
  • High Estimate 0.74
  • Low Estimate 0.66
  • Prior Year 0.74
  • Growth Rate Est. (year over year) -6.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
40.19 +9.08%
on 05/31/19
44.73 -1.99%
on 06/07/19
+1.56 (+3.69%)
since 05/24/19
3-Month
40.19 +9.08%
on 05/31/19
44.73 -1.99%
on 06/07/19
-0.42 (-0.95%)
since 03/22/19
52-Week
39.48 +11.04%
on 06/28/18
45.62 -3.90%
on 11/09/18
+3.84 (+9.60%)
since 06/22/18

Most Recent Stories

More News
Sanofi/Regeneron's Asthma Candidate Meets Goal in Study

Sanofi/Regeneron's IL-33 antibody REGN3500 meets primary endpoint in phase II study in asthma. It does not show increased benefit compared to Dupixent.

MRK : 85.51 (+1.11%)
ABBV : 78.45 (-0.42%)
REGN : 312.55 (-2.41%)
SNY : 43.84 (-0.70%)
Pharma Stock Roundup: ASCO Update, FDA Nod for LLY's Emgality for Cluster Headache

Pharma bigwigs present data from cancer studies at ASCO. Lilly's (LLY) CGRP Emgality gets FDA approval for episodic cluster headache in adults.

AZN : 41.49 (+0.31%)
MRK : 85.51 (+1.11%)
JNJ : 143.06 (+0.68%)
LLY : 115.63 (+0.12%)
RHHBY : 35.3850 (-0.60%)
SNY : 43.84 (-0.70%)
BMY : 45.68 (-7.42%)
Novartis Appoints New Pharma Unit Head, Gives Other Updates

Novartis (NVS) appoints Marie-France Tschudin as head of the pharma unit. The company also provides a few pipeline updates.

CELG : 93.47 (-5.50%)
NVS : 92.80 (+0.34%)
BMY : 45.68 (-7.42%)
SNY : 43.84 (-0.70%)
Was ASCO Quieter for Big Drug/Biotech Stocks This Year?

The annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago sees cancer data presentations from several drug/biotech companies about the latest developments in treating cancer.

AZN : 41.49 (+0.31%)
MRK : 85.51 (+1.11%)
NVS : 92.80 (+0.34%)
RHHBY : 35.3850 (-0.60%)
AMGN : 184.83 (-1.22%)
SNY : 43.84 (-0.70%)
BMY : 45.68 (-7.42%)
Glaxo's Nucala Gets CHMP Nod for 2 Self-Administered Options

GlaxoSmithKline (GSK) announces that the EMA???s Committee for Medicinal Products for Human Use has issued a positive opinion for two self-administered options of its asthma drug, Nucala.

AZN : 41.49 (+0.31%)
REGN : 312.55 (-2.41%)
GSK : 40.59 (+0.79%)
SNY : 43.84 (-0.70%)
Emergent (EBS) Wins HHS Contract to Supply VIGIV Product

Shares of Emergent (EBS) rise after the company gets a 10-year HHS contract valued at roughly $535 million to dispense VIGIV product to the U.S. government for supporting its smallpox awareness drive.

EBS : 45.72 (-1.36%)
ACOR : 7.40 (-1.20%)
GSK : 40.59 (+0.79%)
SNY : 43.84 (-0.70%)
Amarin Rises on Priority Review for Vascepa Label Expansion

Amarin's (AMRN) label expansion application for hypertriglyceridemia drug, Vascepa, gets priority review from the FDA.

ANIK : 38.84 (-3.36%)
AMRN : 18.42 (-3.10%)
AMGN : 184.83 (-1.22%)
SNY : 43.84 (-0.70%)
BioMarin Announces Data on Hemophilia Candidate, Shares Fall

BioMarin (BMRN) announces significant reduction in annual bleed rate in phase III study evaluating gene therapy, valoctocogene roxaparvovec, in hemophilia A patients. However, investors are skeptical.

BAYRY : 15.7300 (+1.29%)
BMRN : 85.90 (-2.29%)
ALNY : 71.80 (-3.46%)
SNY : 43.84 (-0.70%)
Alphabet to Aid Pharma Giants Enhance Clinical Trial Process

Alphabet's (GOOGL) Verily joins hands with Novartis, Sanofi, Otsuka and Pfizer to revolutionize the clinical trial methods.

GOOGL : 1,116.70 (-0.77%)
NVS : 92.80 (+0.34%)
PFE : 43.76 (+0.21%)
SNY : 43.84 (-0.70%)
Pfizer's Eczema Candidate Meets All Goals in Phase III Study

Pfizer's (PFE) investigational eczema treatment abrocitinib succeeds in pivotal late-stage study.

LLY : 115.63 (+0.12%)
REGN : 312.55 (-2.41%)
PFE : 43.76 (+0.21%)
SNY : 43.84 (-0.70%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average.

See More Share

Trade SNY with:

Business Summary

Sanofi-Aventis is a global pharmaceutical company that contributes to enhance life by providing medicines, vaccines, and integrated healthcare solutions adapted to local needs and means primarily in Europe and the United States. The company is engaged in the research, development, manufacture and marketing...

See More

Key Turning Points

2nd Resistance Point 44.10
1st Resistance Point 43.97
Last Price 43.84
1st Support Level 43.73
2nd Support Level 43.61

See More

52-Week High 45.62
Last Price 43.84
Fibonacci 61.8% 43.27
Fibonacci 50% 42.55
Fibonacci 38.2% 41.83
52-Week Low 39.48

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar